Acorn Bioventures

Acorn Bioventures is a New York-based investment firm specializing in early-stage biotechnology and life sciences companies. With over 35 years of experience, they provide flexible investment options and support throughout the entire financing process, from seed funding to IPOs and beyond. Driven by their commitment to fundamental research and partnering with exceptional management teams, Acorn Bioventures has a successful track record of investing in private and small-cap public biotech companies. Their portfolio includes notable investments such as Anacor, GW Pharma, and Tesaro, many of which have grown into multi-billion-dollar enterprises with approved therapies.

Acorn Bioventures focuses on sectors related to biotechnology, pharmaceuticals, and medical devices, aiming to support innovative companies that are dedicated to developing groundbreaking medicines for patients. Their investment strategy emphasizes flexibility and comprehensive support, catering to various stages of company development, from seed funding to pre-IPO stages. This approach allows them to adapt to the unique needs of each portfolio company, fostering growth and success in the competitive biotech industry.

The firm's leadership includes founder and partner Anders Hove, who has a background in managing general partnerships at Venrock. Under his guidance, Acorn Bioventures has established itself as a significant player in the biotech investment landscape, contributing to the advancement of medical treatments and therapies through strategic investments and partnerships.